Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

106.13
-1.0400-0.97%
Post-market: 106.950.8200+0.77%17:12 EDT
Volume:775.19K
Turnover:81.71M
Market Cap:7.31B
PE:-34.05
High:108.85
Open:106.01
Low:103.98
Close:107.17
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:2.08
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:70.96
PE(LYR):-34.13

Loading ...

Rhythm Pharmaceuticals - Estimates Non-Gaap Operating Expenses $363 Mln-$397 Mln for Year Ending Dec 31, 2026

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial That Showed Rm-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Two Participants Discontinued Rm-718 Treatment Due to Adverse Events

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports 11.6% Mean Bmi Reduction at Week 16 in Phase 2 Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Rm-718 Generally Well Tolerated with Most Common Adverse Events Injection Site Reactions, Nausea, Vomiting

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports Two Mild Cases of Injection Site Hyperpigmentation in Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Eight Patients Remain on Active Treatment as of July 16, 2026

THOMSON REUTERS
·
Aug 04

Earning Preview: Rhythm Pharmaceuticals Inc. Q2 revenue is expected to increase by 54.19%, and institutional views are bullish

Earnings Agent
·
Jul 29

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 27

Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 16

Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM

TIPRANKS
·
Jul 16

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 15

Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)?

Simply Wall St.
·
Jul 13

Rhythm Pharmaceuticals Announces the New England Journal of Medicine Publication of Phase 3 Transcend Trial Results in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Jul 09

Medicare Coverage Could Put These Obesity Drug Stocks In Focus

Simply Wall St.
·
Jun 30

Rhythm Pharmaceuticals on Track for Highest Close Since January

Dow Jones
·
Jun 25

Rhythm Pharma Director Lynn A. Tetrault Disposes of Common Shares Worth $3.71 Million

Reuters
·
Jun 25

Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative

Simply Wall St.
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jun 17

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 17